{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:24Z","timestamp":1781085984415,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20H05798"],"award-info":[{"award-number":["20H05798"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16448"],"award-info":[{"award-number":["19K16448"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a mixed approach that combines 2 methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83; 95% confidence interval [CI]: 1.43\u201310.26) but not DAP-related myopathy (OR: 1.72; 95% CI: .95\u20133.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69; 95% CI: 4.31\u20137.51) and rhabdomyolysis (ROR: 5.77; 95% CI: 4.33\u20137.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac128","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T12:29:16Z","timestamp":1645532956000},"page":"1416-1422","source":"Crossref","is-referenced-by-count":31,"title":["Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-283X","authenticated-orcid":false,"given":"Masayuki","family":"Chuma","sequence":"first","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"},{"name":"Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University , Asahikawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital , Urayasu, Chiba , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"},{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University , Bunkyo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima , Japan"},{"name":"Department of Pharmacy, Okayama University Hospital , Kita-ku, Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"},{"name":"Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University , Matsuyama, Ehime , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Graduate School of Biomedical Sciences, Tokushima University , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University , Asahikawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima ; Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2022101219183582900_CIT0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for gram-positive infections.","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2022101219183582900_CIT0002","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.clinthera.2004.11.014","article-title":"Daptomycin: a cyclic lipopeptide antimicrobial agent.","volume":"26","author":"Jeu","year":"2004","journal-title":"Clin Ther"},{"key":"2022101219183582900_CIT0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/1060028013514377","article-title":"Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy.","volume":"48","author":"Berg","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2022101219183582900_CIT0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2022101219183582900_CIT0005","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (&gt;6\u00a0mg\/kg\/day) daptomycin in patients with concomitant statin therapy.","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022101219183582900_CIT0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-014-0041-y","article-title":"Effect of concomitant 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor therapy on creatine phosphokinase levels and mortality among patients receiving daptomycin: retrospective cohort study.","volume":"3","author":"McConnell","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2022101219183582900_CIT0007","volume-title":"Drug approval package","author":"Cubicin (daptomycin) injection.","year":"2003"},{"key":"2022101219183582900_CIT0008","first-page":"75","article-title":"Statins, muscle disease and mitochondria.","volume":"6","author":"Ramachandran","year":"2017","journal-title":"J Clin Med Res"},{"key":"2022101219183582900_CIT0009","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022101219183582900_CIT0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nmd.2014.05.005","article-title":"Rhabdomyolysis: review of the literature.","volume":"24","author":"Zutt","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"2022101219183582900_CIT0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of statin intolerance in 2018: still more questions than answers.","volume":"18","author":"Toth","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022101219183582900_CIT0012","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/AAC.02910-14","article-title":"Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.","volume":"58","author":"Bland","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022101219183582900_CIT0013","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy.","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022101219183582900_CIT0014","doi-asserted-by":"crossref","first-page":"ofz444","DOI":"10.1093\/ofid\/ofz444","article-title":"Retrospective multisite case-control series of concomitant use of daptomycin and statins and the effect on creatine phosphokinase.","volume":"6","author":"Lehman","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022101219183582900_CIT0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022101219183582900_CIT0016","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","article-title":"Statin treatment withdrawal in ischemic stroke: a controlled randomized study.","volume":"69","author":"Blanco","year":"2007","journal-title":"Neurology"},{"key":"2022101219183582900_CIT0017","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1001\/archinte.164.19.2162","article-title":"Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.","volume":"164","author":"Spencer","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022101219183582900_CIT0018","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.chest.2017.12.008","article-title":"Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension: a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the World Health Organization pharmacovigilance database.","volume":"154","author":"Khouri","year":"2018","journal-title":"Chest"},{"key":"2022101219183582900_CIT0019","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.acvd.2020.03.014","article-title":"Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and\/or mitogen-activated extracellular signal-regulated kinase inhibitors: a mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.","volume":"113","author":"Dolladille","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2022101219183582900_CIT0020","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022101219183582900_CIT0021","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity.","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2022101219183582900_CIT0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2022101219183582900_CIT0023","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2022101219183582900_CIT0024","author":"US Food & Drug Administration."},{"key":"2022101219183582900_CIT0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer.","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022101219183582900_CIT0026","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2020.10.041","article-title":"Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity.","volume":"99","author":"Hamano","year":"2021","journal-title":"Kidney Int"},{"key":"2022101219183582900_CIT0027","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00264-013-1856-y","article-title":"The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections.","volume":"37","author":"Jugun","year":"2013","journal-title":"Int Orthop"},{"key":"2022101219183582900_CIT0028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-13-66","article-title":"Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.","volume":"13","author":"Lai","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2022101219183582900_CIT0029","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bcp.15063","article-title":"Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods.","volume":"88","author":"Imai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2022101219183582900_CIT0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2014.4364","article-title":"Can the learning health care system be educated with observational data?","volume":"312","author":"Dahabreh","year":"2014","journal-title":"JAMA"},{"key":"2022101219183582900_CIT0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcpt.13618","article-title":"Risk of muscle toxicity events for daptomycin with and without statins: analysis of the Japanese Adverse Event Report database.","volume":"129","author":"Yamada","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac128\/43370551\/ciac128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1416\/46468755\/ciac128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1416\/46468755\/ciac128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T19:19:49Z","timestamp":1665602389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/8\/1416\/6545825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac128","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,15]]},"published":{"date-parts":[[2022,3,9]]}}}